62 related articles for article (PubMed ID: 7752076)
1. Intact cell binding and the relation to opioid activities in SH-SY5Y cells.
Toll L
J Pharmacol Exp Ther; 1995 May; 273(2):721-7. PubMed ID: 7752076
[TBL] [Abstract][Full Text] [Related]
2. Differential regulation of mu and delta opiate receptors by morphine, selective agonists and antagonists and differentiating agents in SH-SY5Y human neuroblastoma cells.
Zadina JE; Harrison LM; Ge LJ; Kastin AJ; Chang SL
J Pharmacol Exp Ther; 1994 Sep; 270(3):1086-96. PubMed ID: 7932156
[TBL] [Abstract][Full Text] [Related]
3. Mu opiate receptor down-regulation by morphine and up-regulation by naloxone in SH-SY5Y human neuroblastoma cells.
Zadina JE; Chang SL; Ge LJ; Kastin AJ
J Pharmacol Exp Ther; 1993 Apr; 265(1):254-62. PubMed ID: 8097244
[TBL] [Abstract][Full Text] [Related]
4. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
5. H-D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2: a potent and selective antagonist opioid receptors.
Gulya K; Lui GK; Pelton JT; Kazmierski W; Hruby VJ; Yamamura HI
NIDA Res Monogr; 1986; 75():209-12. PubMed ID: 2893264
[TBL] [Abstract][Full Text] [Related]
6. Comparison of mu opioid receptor binding on intact neuroblastoma cells with guinea pig brain and neuroblastoma cell membranes.
Toll L
J Pharmacol Exp Ther; 1992 Jan; 260(1):9-15. PubMed ID: 1346168
[TBL] [Abstract][Full Text] [Related]
7. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
8. Interactions among mu- and delta-opioid receptors, especially putative delta1- and delta2-opioid receptors, promote dopamine release in the nucleus accumbens.
Hirose N; Murakawa K; Takada K; Oi Y; Suzuki T; Nagase H; Cools AR; Koshikawa N
Neuroscience; 2005; 135(1):213-25. PubMed ID: 16111831
[TBL] [Abstract][Full Text] [Related]
9. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier permeability and bioavailability of a highly potent and mu-selective opioid receptor antagonist, CTAP: comparison with morphine.
Abbruscato TJ; Thomas SA; Hruby VJ; Davis TP
J Pharmacol Exp Ther; 1997 Jan; 280(1):402-9. PubMed ID: 8996221
[TBL] [Abstract][Full Text] [Related]
11. Delta opioid receptor enhancement of mu opioid receptor-induced antinociception in spinal cord.
He L; Lee NM
J Pharmacol Exp Ther; 1998 Jun; 285(3):1181-6. PubMed ID: 9618421
[TBL] [Abstract][Full Text] [Related]
12. Chronic agonist treatment converts antagonists into inverse agonists at delta-opioid receptors.
Liu JG; Prather PL
J Pharmacol Exp Ther; 2002 Sep; 302(3):1070-9. PubMed ID: 12183665
[TBL] [Abstract][Full Text] [Related]
13. A single residue, Lys108, of the delta-opioid receptor prevents the mu-opioid-selective ligand [D-Ala2,N-MePhe4,Gly-ol5]enkephalin from binding to the delta-opioid receptor.
Minami M; Nakagawa T; Seki T; Onogi T; Aoki Y; Katao Y; Katsumata S; Satoh M
Mol Pharmacol; 1996 Nov; 50(5):1413-22. PubMed ID: 8913373
[TBL] [Abstract][Full Text] [Related]
14. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
Siehler S; Nunn C; Zupanc GK; Hoyer D
Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
[TBL] [Abstract][Full Text] [Related]
15. Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.
Szücs M; Boda K; Gintzler AR
J Pharmacol Exp Ther; 2004 Jul; 310(1):256-62. PubMed ID: 14996951
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a novel class of neuromedin B receptor antagonists, substituted somatostatin analogues.
Orbuch M; Taylor JE; Coy DH; Mrozinski JE; Mantey SA; Battey JF; Moreau JP; Jensen RT
Mol Pharmacol; 1993 Oct; 44(4):841-50. PubMed ID: 7901752
[TBL] [Abstract][Full Text] [Related]
17. Mu-opioid receptor binding in intact SH-SY5Y neuroblastoma cells.
Toll L
Eur J Pharmacol; 1990 Feb; 176(2):213-7. PubMed ID: 1968847
[TBL] [Abstract][Full Text] [Related]
18. Novel sst(4)-selective somatostatin (SRIF) agonists. 3. Analogues amenable to radiolabeling.
Erchegyi J; Waser B; Schaer JC; Cescato R; Brazeau JF; Rivier J; Reubi JC
J Med Chem; 2003 Dec; 46(26):5597-605. PubMed ID: 14667214
[TBL] [Abstract][Full Text] [Related]
19. Adrenal medullary opiate receptors. Pharmacological characterization in bovine adrenal medulla and a human pheochromocytoma.
Castanas E; Giraud P; Audigier Y; Drissi R; Boudouresque F; Conte-Devolx B; Oliver C
Mol Pharmacol; 1984 Jan; 25(1):38-45. PubMed ID: 6323951
[TBL] [Abstract][Full Text] [Related]
20. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
